- Senate passes Drug Quality and Security Act
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Study from NCPA sheds new light on med synchronization programs
NEW YORK — While most of the attention to the Prescription Drug User Fee Act reauthorization focused on what it would mean for the generic drug industry, one other aspect of the law recently drew applause from a group that advocates on behalf of the blind.
The Food and Drug Administration Safety and Innovation Act, which President Barack Obama signed into law this week, included provisions that establish best practices for pharmacies to use in providing accessible prescription drug labeling to patients with vision loss, including proper dosage, the name of the medication, safety information and more.
"We applaud President Obama and Congress for taking this important step," American Foundation for the Blind president and CEO Carl Augusto said. "AFB has been working on this issue for many years, and we're thrilled that this is now a reality."